DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading
DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading portal core
9 articles
Teclistamab is no longer just a late-line myeloma option; phase III data push it earlier into the clinical argument.
A large genetic study of feline tumors turns house cats from a poorly mapped patient population into a serious model for understanding human cancer.
CAR T therapy, one of modern oncology’s most aggressive tools, is now being tested in autoimmune disease, where the target is no longer a tumor but an immune system attacking its own body.
MYC, long known for driving tumor growth, may also move directly into damaged DNA and help cancer cells repair the very injuries caused by therapy.
Preclinical work at McMaster University suggests a new drug candidate can eliminate glioblastoma tumors in models that usually resist standard treatment.
Pretargeted alpha therapy shows striking results in tumor models, but the clinical message must stay precise: this is not yet proof of a human therapy.
Rosie the Staffordshire terrier’s skin cancer treatment—allegedly designed with ChatGPT—has no peer-reviewed backing, yet the story went viral anyway.
Texas A&M researchers found FGFR1 boosts cholesterol uptake in prostate cancer cells, fueling tumor growth and therapy resistance.
New method measures cancer’s hidden gene-splicing toolkit, proving tumors weaponize RNA editing to fuel growth and survival.
